Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor-Reference-Cited by-同舟云学术

Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor

Published:2022-12-26 Issue:1 Volume:66 Page:695-715
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kanada Ryutaro¹^ORCID,Kagoshima Yoshiko¹,Suzuki Takashi¹,Nakamura Akifumi¹,Funami Hideaki¹,Watanabe Jun¹,Asano Masayoshi¹,Takahashi Mizuki²^ORCID,Ubukata Osamu²,Suzuki Kanae¹,Aikawa Tomoya¹,Sato Kazumi²,Goto Megumi¹,Setsu Genzui¹,Ito Kentaro¹,Kihara Kawori²,Kuroha Mutsumi²,Kohno Takashi³,Ogiwara Hideaki⁴,Isoyama Takeshi¹,Tominaga Yuichi¹,Higuchi Saito¹,Naito Hiroyuki¹

Affiliation:

1. Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo140-8710, Japan

2. Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo134-8630, Japan

3. Division of Genome Biology, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo104-0045, Japan

4. Division of Cancer Therapeutics, National Cancer Center Research Institute, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo104-0045, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01641

Reference25 articles.

1. CREB-binding Protein and p300 in Transcriptional Regulation

2. CBP/p300 in cell growth, transformation, and development

3. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation

4. Histone acetylation: a switch between repressive and permissive chromatin

5. The Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery Small-Molecule p300 Inhibitors Derived from a Newly Developed Indazolone-Focused DNA-Encoded Library;Bioconjugate Chemistry;2024-08-08

2. Method for Synthesis of 4-(4-Hydroxyphenyl)cycloalkanedicarboxylic Acids Based on SEAr Alkylation;Журнал общей химии;2024-07-23

3. Discovery of an EP300 Inhibitor using Structure-based Virtual Screening andBioactivity Evaluation;Current Pharmaceutical Design;2024-07

4. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy;eBioMedicine;2024-07

5. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer;Journal of Medicinal Chemistry;2024-03-26